KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Retained Earnings (2016 - 2025)

CRISPR Therapeutics AG's Retained Earnings history spans 11 years, with the latest figure at -$1.9 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 42.58% year-over-year to -$1.9 billion; the TTM value through Dec 2025 reached -$1.9 billion, down 42.58%, while the annual FY2025 figure was -$1.9 billion, 42.58% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.9 billion at CRISPR Therapeutics AG, down from -$1.8 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $72.5 million in Q2 2021 and bottomed at -$1.9 billion in Q4 2025.
  • The 5-year median for Retained Earnings is -$792.9 million (2021), against an average of -$740.7 million.
  • The largest annual shift saw Retained Earnings surged 119.38% in 2021 before it crashed 96675.0% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$5.1 million in 2021, then plummeted by 208.8% to -$15.6 million in 2022, then plummeted by 6289.08% to -$999.7 million in 2023, then crashed by 36.64% to -$1.4 billion in 2024, then plummeted by 42.58% to -$1.9 billion in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Retained Earnings are -$1.9 billion (Q4 2025), -$1.8 billion (Q3 2025), and $4.0 million (Q2 2025).